Pimavanserin Resubmitted to FDA; APA’s New President Elect; Bipolar Market Slowing

After the FDA turned down its request to expand the label for pimavanserin (Nuplazid), Acadia Pharmaceuticals resubmitted its supplemental new drug application for a more narrow indication — treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

Over a 10-year period, U.S.-based clinical trials for eating disorders largely excluded older adults, men, and racial and ethnic minority groups. (JAMA Network Open)

Petros Levounis, MD, MA, of Rutgers New Jersey Medical School, was voted in as the American Psychiatric Association’s next president-elect, assuming the role in May 2023.

An estimated 2.6 million U.S. adults — accounting for 9.1% of all opioid users and 18.4% of high-volume prescription opioid users — receive a combination of an opioid, benzodiazepine, and non-benzodiazepine sedative medication. (Regional Anesthesia & Pain Medicine)

A new analysis from GlobalData found that despite the launch of seven new pipeline agents, the bipolar disorder market will only see “modest” growth due to generic erosion.

Many people who used drugs as teens but quit before adulthood still experienced successes in life. “What seems to best predict low life success outcomes is the persistence (over a longer course of time) of cannabis and amphetamine use,” said study author Jake Najman, PhD, of the University of Queensland in Australia. (Addiction Research & Theory)

A Connecticut psychiatric practice and its owner paid $310,000 in a civil settlement agreement for allegedly improperly employing a convicted physician, who was subsequently excluded from all federal healthcare programs. (Department of Justice)

After raising $25 million, the psychiatry startup digital platform Minded said its focus is on providing users with greater access to prescription medications for anxiety, depression, and insomnia. (FierceHealthcare)